This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GNC Holdings Launches Energy Drink With Natural Extracts
by Zacks Equity Research
GNC Holdings (GNC) launches natural ingredient-based energy drink MAD PONY ENERGY.
NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Neogen's (NEOG) Soleris for EBAC Receives AOAC's Clearance
by Zacks Equity Research
Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.
EYE vs. AHCO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. AHCO: Which Stock Is the Better Value Option?
Zimmer Biomet Focuses on Priority Areas Despite Pricing Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.
Medtronic's (MDT) Brain Therapies Device Receives FDA Approval
by Zacks Equity Research
Medtronic (MDT) strengthens its robotics platform with the receipt of regulatory approval and the subsequent upgradation of its enabling technology portfolio.
Medtronic Acquires Klue to Strengthen Diabetes Management Arm
by Zacks Equity Research
Medtronic (MDT) strengthens its diabetes business through the Klue acquisition and subsequent development of its PCL technology.
Globus Medical Rides on New Product Menu, U.S. Spine Business
by Zacks Equity Research
Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.
Boston Scientific Hits New 52-Week High: What's Driving it?
by Zacks Equity Research
Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.
Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod
by Zacks Equity Research
Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.
Bruker Launches Luxendo TruLive3D Imager, Expands NANO Arm (Revised)
by Zacks Equity Research
Bruker's (BRKR) latest Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environments.
CVS Health Rides on Aetna Prospects, Strong Selling Season
by Zacks Equity Research
CVS Health's (CVS) 2020 PBM selling season is approaching closure and the 2021 selling season is ongoing.
Omnicell-Huron Sign a Pact for Outcome-Based Expert Services
by Zacks Equity Research
Omnicell (OMCL) partners Huron to provide customers with committed expertise.
Bruker Launches Luxendo TruLive3D Imager in Mass Spectrometry
by Zacks Equity Research
Bruker's (BRKR) Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environment.
Globus Medical Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.
NuVasive Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
NuVasive (NUVA) is optimistic about maintaining the momentum on several positive developments.
TransMedics' OCS Technology Sees Success in Heart Transplant
by Zacks Equity Research
TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.
National Vision (EYE) Up 3.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell to Feature Upgrades in Medication Management at ASHP
by Zacks Equity Research
Omnicell (OMCL) to showcase innovations in medication management solution portfolio to minimize human errors by care providers.
New Strong Buy Stocks for December 6th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Myriad Genetics Reports Favorable Study Result on Prequel
by Zacks Equity Research
Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.
NuVasive Advances on Global Footprint Despite Pricing Woes
by Zacks Equity Research
Within NuVasive's (NUVA) U.S. Spinal Hardware business, a strong uptick in case volume and tangible growth in the XLIF and ALIF franchises are major upsides.
Haemonetics (HAE) Launches SafeTrace Tx in North America
by Zacks Equity Research
Haemonetics (HAE) expands the transfusion management portfolio with SafeTrace Tx, the latest in its transfusion management software product line.
Thermo Fisher Rides on New Product Suite and Global Growth
by Urmimala Biswas
A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.
EYE or NEOG: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. NEOG: Which Stock Is the Better Value Option?